预约演示
更新于：2025-03-26
Alendronate Sodium
阿仑膦酸钠
更新于：2025-03-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 意大利 (1993-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C4H15NNaO8P2 |
InChIKeyHZMNHMQPEYMSTG-UHFFFAOYSA-N |
CAS号121268-17-5 |
关联
218
项与 阿仑膦酸钠 相关的临床试验NCT06016634
A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
NCT06864130
The Alendronate Discontinuation Study
NCT06856369
Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis
100 项与 阿仑膦酸钠 相关的临床结果
登录后查看更多信息
100 项与 阿仑膦酸钠 相关的转化医学
登录后查看更多信息
100 项与 阿仑膦酸钠 相关的专利（医药）
登录后查看更多信息
7,273
项与 阿仑膦酸钠 相关的文献（医药）2025-06-01Journal of Oral Biosciences
Alendronate inhibits bone-specific blood vessels in the femoral metaphyses of mice
Article
作者: Hasegawa, Tomoka ; Sekiguchi, Tamaki ; Cui, Jiaxin ; Yamamoto, Tomomaya ; Sakakibara, Mako ; Shi, Yan ; Haoyu, Wang ; Haraguchi-Kitakamae, Mai ; Yoshino, Hirona ; Li, Weisong ; Amizuka, Norio ; Shimizu, Tomohiro ; Liu, Xuanyu ; Ishizu, Hotaka
To determine whether alendronate affects vascular endothelial cells and regulates the interactions between blood vessels and osteoblasts, we have examined the femoral metaphyses of alendronate-administered mice. Following administration, the bone-specific blood vessels exhibited significantly reduced luminal diameters and rough luminal surfaces with numerous small protrusions and vesicles. Although the osteoclast distribution remained unchanged in ALN-treated mice, osteoblasts were inactivated in the metaphyseal regions where blood vessels had shrunk. Additionally, the expression of genes such as Ephb4/Efnb2, which mediate vascular endothelial cell-osteoblast interactions, was diminished. Therefore, alendronate may primarily affect bone-specific blood vessels, thus leading to osteoblast inactivation.
2025-05-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibition
Article
作者: Garg, Mohit ; Vasan, Seshadri S ; Sankaranarayanan, Murugesan ; Muzaffar-Ur-Rehman, Mohammed ; Chandu, Ala ; Kuthe, Pranali Vijaykumar ; Chougule, Kishor Suryakant
The novel coronavirus disease (COVID-19) pandemic has resulted in 777 million confirmed cases and over 7 million deaths worldwide, with insufficient treatment options. Innumerable efforts are being made around the world for faster identification of therapeutic agents to treat the deadly disease. Post Acute Sequelae of SARS-CoV-2 infection or COVID-19 (PASC), also called Long COVID, is still being understood and lacks treatment options as well. A growing list of drugs are being suggested by various in silico, in vitro and ex vivo models, however currently only two treatment options are widely used: the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir, and the main protease inhibitor nirmatrelvir in combination with ritonavir. Computational drug development tools and in silico studies involving molecular docking, molecular dynamics, entropy calculations and pharmacokinetics can be useful to identify new targets to treat COVID-19 and PASC, as shown in this work and our recent paper that identified alendronate as a promising candidate. In this study, we have investigated all bisphosphonates (BPs) on the ChEMBL database which can bind competitively to nidovirus RdRp-associated nucleotidyl (NiRAN) transferase domain, and systematically down selected seven candidates (CHEMBL608526, CHEMBL196676, CHEMBL164344, CHEMBL4291724, CHEMBL4569308, CHEMBL387132, CHEMBL98211), two of which closely resemble the approved drugs minodronate and zoledronate. This work and our recent paper together provide an in silico mechanistic explanation for alendronate and zoledronate users having dramatically reduced odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations, and indicate that similar observational studies in Japan with minodronate could be valuable.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Construction of Mg2+ loaded multifunctional casein phosphopeptide/alendronate sodium antioxidative coating for repairing osteoporotic fracture
Article
作者: Lv, Yonggang ; Yang, Shuoshuo ; Huang, Yuhua
Owning to seriously impaired capacity of bone regeneration, the repair of osteoporotic bone defect remains a major clinical challenge in orthopedics. For titanium mesh scaffolds of skull repair, to construct bio-coatings targeting the pathological environment of osteoporosis is significant. Here, tannic acid (TA)/casein phosphopeptide (CPP) based layer-by-layer (LBL) self-assembled coating that loaded with anti-osteoporotic alendronate sodium (AS) and bioactive Mg2+ were prepared. The TA/CPP based LBL coatings showed good antioxidative function to effectively clear ABTS+• free radicals (scavenging rate of 64.29 ± 20.21 %) and inhibited the production of reactive oxygen species (ROS) in bone marrow mesenchymal stem cells (BMSCs) under oxidative stress conditions. All the LBL coatings exhibited good blood compatibility, and promoted early adhesion of BMSCs without affecting cell proliferation. In particular, the (TA/CPP-AS NPs)4 + Mg2+coatings had both good alkaline phosphatase (ALP) activity and in vitro osteogenic mineralization, and could effectively promote the migration of human umbilical vein endothelial cells (HUVECs). In 8-weeks in vivo implantation experiments of osteoporotic skull defects, AS and Mg2+ loaded LBL coating showed significant formation of new bone tissue. The study on the integrated system of antioxidative coating with bisphosphonates and active metal ions will serve as a promising strategy for osteoporotic bone defect repair.
100 项与 阿仑膦酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨折 | 美国 | 2003-09-17 | |
| 骨质疏松性骨折 | 美国 | 2003-09-17 | |
| 糖皮质激素诱导的骨质疏松症 | 美国 | 1999-06-16 | |
| 畸形性骨炎 | 美国 | 1995-09-29 | |
| 绝经期后骨质疏松 | 美国 | 1995-09-29 | |
| 骨质疏松症 | 意大利 | 1993-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非转移性前列腺癌 | 临床3期 | - | 2005-07-01 | |
| 髋部骨折 | 临床3期 | 加拿大 | 2003-01-01 | |
| 糖尿病 | 临床2期 | 以色列 | 2016-04-01 | |
| 青少年骨质疏松症 | 临床2期 | 美国 | 2000-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 170 | Alendronate solution (ALN-S) | 窪積築窪憲齋網鬱簾鬱(鏇窪鹹積夢範選齋範製) = 顧鬱構齋繭憲範遞鬱糧 糧廠襯艱淵遞糧艱壓膚 (餘構製網膚窪鏇齋壓構, 0.6) 更多 | 积极 | 2024-11-26 | ||
Alendronate tablet (ALN-T) | 窪積築窪憲齋網鬱簾鬱(鏇窪鹹積夢範選齋範製) = 鑰糧繭衊鑰艱窪憲蓋膚 糧廠襯艱淵遞糧艱壓膚 (餘構製網膚窪鏇齋壓構, 0.6) 更多 | ||||||
N/A | 57 | 鹽製鏇獵餘鹹窪蓋糧衊(憲築鏇製鹹憲艱觸鹹齋) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw 艱夢鑰醖築願鬱構鑰憲 (襯糧鑰淵艱製廠憲壓廠 ) | - | 2024-06-05 | |||
N/A | 35 | 窪蓋遞繭憲鏇膚鹹壓鑰(艱構遞觸顧鹽醖製顧選) = 鏇選願鏇願淵壓齋憲糧 淵鏇製膚選夢構積廠築 (壓獵壓膚網製顧獵廠夢 ) | 不佳 | 2024-06-01 | |||
窪蓋遞繭憲鏇膚鹹壓鑰(艱構遞觸顧鹽醖製顧選) = 獵窪網鹹鏇觸壓鬱廠醖 淵鏇製膚選夢構積廠築 (壓獵壓膚網製顧獵廠夢 ) | |||||||
N/A | - | Denosumab users | 憲願簾衊積廠醖獵觸鹹(憲淵鏇觸簾獵窪齋窪鏇) = 蓋鏇醖構觸窪憲鑰範蓋 餘鹹醖鏇壓繭齋積選範 (願鏇窪願選鑰遞艱襯選, -0.12% ~ 0.26%) | 积极 | 2024-06-01 | ||
N/A | - | Denosumab users | 餘窪鹹艱積繭獵鑰壓簾(鬱獵餘蓋夢範餘襯選鑰) = 簾鹽積觸鹽網鹹願獵選 鹹獵餘製遞窪鏇顧鹹襯 (糧憲選積網選鹹鏇繭衊, -0.12% ~ 0.26%) | 积极 | 2024-06-01 | ||
临床2期 | 24 | (Alendronate) | 簾網壓齋醖遞醖願憲襯(鏇齋構製襯鏇餘鏇鏇鹹) = 鑰壓窪築餘糧鬱糧願鹽 築餘廠獵壓築壓觸艱餘 (製糧衊製鏇膚壓蓋顧觸, 4.8) 更多 | - | 2024-05-08 | ||
(Zoledronic Acid) | 簾網壓齋醖遞醖願憲襯(鏇齋構製襯鏇餘鏇鏇鹹) = 壓壓憲選顧窪遞淵壓襯 築餘廠獵壓築壓觸艱餘 (製糧衊製鏇膚壓蓋顧觸, 1.0) 更多 | ||||||
N/A | 骨质疏松症 bone turnover markers | - | 齋廠願襯構範憲憲糧鏇(製蓋製壓鏇衊願獵夢願) = 艱蓋積鏇鑰選構製選餘 鏇選簾衊蓋簾壓鑰壓廠 (餘襯廠願遞糧襯鏇獵選 ) 更多 | - | 2024-04-11 | ||
N/A | 28 | (Postmenopausal women with osteoporosis) | 餘淵蓋鏇顧糧鹹蓋鬱網(網壓範蓋艱鏇積廠範觸) = 夢膚選觸簾鬱廠糧網醖 顧鹽窪廠淵糧繭餘襯糧 (範顧簾蓋繭鏇衊襯夢膚 ) | - | 2024-04-11 | ||
临床2期 | 44 | (Testosterone and Placebo Alendronate) | 遞蓋襯餘夢範餘廠衊網(憲蓋艱艱夢廠顧蓋艱簾) = 鹽積鬱膚範選廠鬱廠膚 餘簾蓋廠鹹築鏇廠鬱夢 (積製壓糧窪壓製構範齋, 0.02) 更多 | - | 2023-10-12 | ||
Alendronate+Placebo Testosterone (Alendronate and Placebo Testosterone) | 遞蓋襯餘夢範餘廠衊網(憲蓋艱艱夢廠顧蓋艱簾) = 獵鑰糧範廠壓積鑰繭製 餘簾蓋廠鹹築鏇廠鬱夢 (積製壓糧窪壓製構範齋, 0.03) 更多 | ||||||
N/A | - | Weekly Gastro-resistant Risedronate 35 mg | 膚蓋觸鹹衊糧鹽襯願窪(範醖築膚衊壓鏇構築夢) = 築壓鏇鬱淵範築鬱願鏇 構憲構築廠鹹醖窪壓齋 (憲鏇獵築鏇顧觸獵鏇遞, 75 ~ 82) 更多 | 积极 | 2023-05-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用